What it is: A synthetic peptide that mimics ghrelin and directly stimulates pituitary GH release; also known as pralmorelin and approved as a diagnostic agent in Japan.
Research suggests: Human studies confirm it produces strong GH pulses; its approval as a diagnostic tool in Japan provides pharmacokinetic and acute safety data unusual for research peptides.
Best for: Growth hormone optimization researchers
Key thing to know: More likely than newer, more selective GHRPs to raise cortisol and prolactin alongside GH; this lack of selectivity is the primary reason ipamorelin is often preferred.
What is GHRP-2?
GHRP-2 (Growth Hormone Releasing Peptide-2), also known as pralmorelin, is a synthetic hexapeptide that acts as a ghrelin mimetic - it binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by ghrelin, the body's endogenous "hunger hormone." GHRP-2 was among the first and most studied members of the GHRP family and has been evaluated in human clinical research more extensively than most peptides in this category.
It was developed as part of research into endogenous GH axis stimulation, with the goal of increasing GH output without the complications and supra-physiological levels associated with exogenous recombinant GH. GHRP-2 is considered one of the more potent GHRPs studied, producing robust GH pulses in both healthy adults and individuals with GH deficiency or axis dysregulation.
Pralmorelin (GHRP-2) reached clinical use in Japan as a diagnostic agent for evaluating GH secretory capacity - one of the few GHRPs to achieve any regulatory approval. This gives it a more established human safety profile than most research peptides, though its use outside diagnostic testing remains off-label and unapproved in most jurisdictions.
How it works.
GHRP-2 binds to GHS-R1a receptors located on somatotroph cells in the anterior pituitary as well as in the hypothalamus and other brain regions. This binding triggers a calcium-dependent intracellular signaling cascade that stimulates the release of stored GH from pituitary somatotrophs. Simultaneously, GHRP-2 suppresses somatostatin - the hypothalamic hormone that normally inhibits GH release - creating a dual mechanism that produces especially robust GH pulses.
Unlike GHRH (growth hormone releasing hormone), which only stimulates new GH synthesis, GHRP-2 primarily acts on stored GH and can produce GH pulses even in contexts where endogenous GHRH signaling is blunted. This makes it a useful research tool for studying GH axis reserve and for evaluating pituitary function - which is why it gained clinical use as a diagnostic agent.
The downstream effects of GHRP-2-induced GH release are mediated through the GH/IGF-1 axis: elevated GH triggers hepatic IGF-1 production, which drives anabolic signaling in muscle, bone, and other tissues. GHRP-2 also has cortisol- and prolactin-stimulating properties via actions on corticotroph and lactotroph cells - a clinically relevant characteristic that distinguishes it from more selective GHRPs like ipamorelin. Research indicates that GHRP-2 produces measurable cortisol elevation at research doses, which is an important consideration for protocol design and monitoring.
What the research shows.
GHRP-2 has one of the more robust human evidence bases among research peptides. Multiple controlled clinical studies have demonstrated that GHRP-2 produces dose-dependent GH release in healthy adults, GH-deficient patients, and elderly subjects with age-related GH axis decline. Studies have measured downstream IGF-1 elevation, changes in body composition (reduced fat mass, increased lean mass), and improvements in sleep quality over extended administration periods.
Its approval as a diagnostic agent in Japan (under the brand name GHRP Kaken) provides a human pharmacokinetic and acute safety profile that most research peptides lack entirely. Studies have characterized its half-life, receptor binding kinetics, and acute adverse effect profile in human subjects - information that exists for very few peptides outside the pharmaceutical development pipeline.
The limitations are that long-term efficacy and safety data for chronic research use (beyond the acute diagnostic context) remain limited. The cortisol-stimulating properties require monitoring in protocols exceeding short-term administration. Large randomized controlled trials evaluating therapeutic outcomes in body composition or recovery contexts have not been conducted.
Biomarkers to review first.
Research protocols for GHRP-2 typically reference the following biomarkers as essential baseline context. Given its effects on cortisol, GH, and broader endocrine signaling, a thorough hormonal baseline is especially important before any protocol consideration.
What it's commonly researched with.
In research literature, GHRP-2 is frequently studied alongside GHRH analogs and other GH secretagogues to amplify or extend GH pulses. The combinations below represent what researchers have studied - not recommendations for use.